Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults

Παρόμοια τεκμήρια

• Single-Dose Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor, in HIV-Infected Children
  ανά: Yogev, Ram, κ.ά.
  Έκδοση: (2005)
• Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro
  ανά: Drusano, G. L., κ.ά.
  Έκδοση: (1998)
• Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease Inhibitors
  ανά: Schmidt, Barbara, κ.ά.
  Έκδοση: (2000)
• Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
  ανά: Sadler, Brian M., κ.ά.
  Έκδοση: (2001)
• Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir
  ανά: Sadler, Brian M., κ.ά.
  Έκδοση: (2001)